Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 10/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 9/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082485 | 0.91 | PTGER2 (0.48) | PTGER2PTGER4 | |
| SCHEMBL4077381 | 0.90 | PTGER4 (0.43) | PTGER2PTGER4MEN1KMT2A | |
| SCHEMBL4082526 | 0.85 | PTGER2 (0.49) | PTGER2PTGER4MEN1KMT2A | |
| SCHEMBL4077690 | 0.80 | PTGER2 (0.59) | PTGER2PTGER4 | |
| SCHEMBL4084920 | 0.78 | PTGER2 (0.49) | PTGER2PTGER4MEN1KMT2A | |
| SCHEMBL4086064 | 0.77 | PTGER4 (0.47) | PTGER2PTGER4MEN1KMT2ALMNA | |
| SCHEMBL1050665 | 0.77 | PTGER2 (0.46) | PTGER2PTGER4 | |
| SCHEMBL4087358 | 0.77 | PTGER4 (0.55) | PTGER2PTGER4MEN1KMT2A | |
| SCHEMBL4084934 | 0.77 | PTGER2 (0.56) | PTGER2PTGER4 | |
| SCHEMBL4408775 | 0.76 | KMT2A (0.46) | PTGER2PTGER4MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | PTGER2 39/4885PTGER4 33/4885MEN1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.